Thrombosis associated with antiphospholipid antibodies (aPL) occurs in both venous and the arterial circulation. The most common arterial thrombo-occlusive event is cerebral infarction. We briefly review treatment strategies aimed at patients with cerebrovascular disease and aPL. Besides general treatment issues, we discuss primary prevention and secondary prevention. Most regimens include antithrombotics or immune modulation. Prospective studies (currently underway) are required to better estimate the rate of recurrent thrombo-occlusive events on standardized therapy before one therapy can be recommended over another with reasonable evidence.
LevineSRWelchKMA. The spectrum of neurologic disease associated with antiphospholipid antibodies: lupus anticoagulants and anticardiolipin antibodies. Arch Neurol1987; 44: 876–883
BrileyDPCoullBMGoodnightSHJr.Neurological disease associated with antiphospholipid antibodies. Ann Neurol1989; 25: 221–227
4.
LevineSRBreyRL. Neurological aspects of antiphospholipid syndrome. Lupus.
5.
CoullBMLevineSRBreyRL. The role of antiphospholipid antibodies and stroke. Neurol Clin1992; 10: 125–143
6.
FeldmannELevineSR. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance and therapeutic options. Ann Neurol1995; 37 (Suppl 1): S114–S130
7.
BreyRL. Stroke prevention in patients with antiphospholipid antibodies. Lupus1994; 3: 299–302
8.
BabikianVLLevineSR. Therapeutic considerations for stroke patients with antiphospholipid antibodies. Stroke1992; 23 (Suppl 2): 33–37
9.
BreyRLCoullBM. Antiphospholipid antibodies: origin, specificity and mechanism of action. Stroke1992; 23 (Suppl 2): 15–18
10.
McNeilHPChestermanCNKrilisSA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol1991; 49: 193–280
11.
BreyRLHartRGShermanDGTegelerCT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology1990; 40: 1190–1196
12.
NenciniPLupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke1992; 23: 189–193
13.
Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology1993; 43: 2069–2073
14.
CamerlingoMAnticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand1995; 92: 60–71
15.
LevineSRRecurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol1995; 38: 119–124
16.
Vasquez-MelladoJLlorenteLRichaud-PatinYAlarcon-SegoviaD. Exposure of anionic phospholipids upon platelet activation permits binding of beta-2-glycoprotein I and through it that of IgG antiphospholipid antibodies. J Autoimmunity1994; 7: 335–348
17.
CampbellALPierangeliSSWellhausenSHarrisEN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemostat1995; 73: 529–534
18.
D'OlhaberriagueLSpecificity of anticardiolipin antibodies in cardiovascular disease. Lupus1996 (in press)
19.
LevineSRDeeganMJFutrellNWelchKMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies. 48 cases. Neurology1990; 40: 1190–1196
20.
VerroPLevineSRTietjenGE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke1995; 26: 160
LovePESantoroSA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Ann Intern Med1990; 112: 682–698
23.
EscalanteABreyRLMitchellBDDreinerU. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med1995; 98: 559–567
24.
RosoveMHBrewerPMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303–308
25.
KhamashtaMAThe management of thrombosis in the antiphospholipid antibody syndrome. New Eng J Med1995; 332: 993–997
26.
Antiphospholipid Antibodies in Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology1996; (in press)
27.
The WARSS, APASS, PICSS and HAS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies and Stroke Study (APASS), the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), and the Hemostatic System Activation Study (HAS). Cerebrovasc Dis1996; (in press)
28.
TietjenGEFactors which predict antiphospholipid immunoreactivity in young people with focal neurologic deficits. Arch Neurol1993; 50: 833–836
29.
TietjenGEDifferentiating TIA from migraine aura in adults under 60 years of age. Stroke1995; 26: 174
